• Vardenafil HCl Trihydrate: PDE5 Research Guide

  2026-08-14

  Vardenafil HCl Trihydrate is a selective PDE5 inhibitor with a reported 0.7 nM in vitro enzymatic IC50. This guide connects its cGMP-linked smooth muscle activity with PDE isoform selectivity, erectile dysfunction models, and proteoform-resolved off-target research.

• Sisomicin: 30S-Targeting Aminoglycoside Research

  2026-08-13

  Sisomicin is a broad-spectrum aminoglycoside antibiotic used in bacterial protein-synthesis and susceptibility research. Product information describes activity against multiple Gram-negative and Gram-positive organisms, while separate MDR-isolate research illustrates why standardized in vitro antibacterial testing is essential before translational interpretation.

• Flubendazole at the Autophagy–Metastasis Interface

  2026-08-13

  A translational framework for using Flubendazole to test how autophagy intersects with macrophage-derived extracellular vesicles, miR-660, KLHL21, and NF-κB signaling in breast cancer models.

• Fasudil (HA-1077) HCl in Hippo–ROCK Assays

  2026-08-12

  Fasudil (HA-1077) HCl is a ROCK inhibitor that can help separate cytoskeletal signaling from Hippo-pathway effects in lens epithelial-cell studies. This article translates recent cataract research into a rigorous, hypothesis-testing assay strategy without overstating Fasudil as a cataract treatment.

• Maraviroc and CCR5: From HIV Entry to EV Biology

  2026-08-12

  Maraviroc, also known as UK-427857, is best known for HIV-1 entry inhibition, but emerging extracellular-vesicle research reveals a broader way to interrogate CCR5 biology. This article translates that finding into practical assay design for HIV tropism, rheumatoid arthritis, and inflammatory signaling studies.

• MDockPeP2_VS for β-Lactamase Peptide Inhibitors

  2026-08-11

  Xu et al. introduce MDockPeP2_VS, a structure-based workflow that uses conservation between protein folding and protein–peptide binding to make large-scale peptide screening more practical. In a TEM-1 β-lactamase demonstration, the workflow identified TF7, which inhibited enzymatic activity with a reported Ki of 1.37 ± 0.37 μM and provides a starting point for experimental β-lactam antibiotic resistance research.

• GMA Refines Jiawei-Xiaoyao’s Rapid Antidepressant Action

  2026-08-10

  This study identifies GMA, a three-herbal refinement of Jiawei-Xiaoyao Pill, as a rapidly acting antidepressant-like formula in normal and LPS-treated mice. Its behavioral and molecular data connect reduced hippocampal neuroinflammation with restoration of CaMKII–mTOR–BDNF neuroplasticity signaling, while mTOR inhibition provides pharmacological support for pathway involvement.

• Wortmannin for PI3K and Autophagy Assays

  2026-08-09

  Wortmannin provides a fast pharmacological test of PI3K dependence in autophagy, apoptosis, and cancer research workflows. Its value is greatest when pathway inhibition is paired with flux measurements, genetic controls, and careful management of concentration-dependent kinase off-targets.

• Berberine Hydrochloride in AMPK Assays

  2026-08-08

  Berberine hydrochloride offers a versatile way to study AMPK-linked metabolic regulation, apoptosis, and ferroptosis. This article presents a cross-domain assay strategy inspired by mitochondrial cardiotoxicity research, emphasizing causal readouts over single endpoint screening.

• Bufuralol Hydrochloride in Organoid PK Workflows

  2026-08-07

  Use Bufuralol hydrochloride to connect β-adrenergic pharmacology with human intestinal absorption and metabolism models. A practical organoid-to-assay workflow helps separate direct receptor effects from exposure, transporter, and CYP3A-related variables.

• Sildenafil Citrate in Proteoform-Resolved Signal Transductio

  2026-08-07

  Explore how Sildenafil Citrate, a cGMP-specific phosphodiesterase type 5 inhibitor, empowers high-resolution research into proteoform-modulated signaling and vascular smooth muscle relaxation. This article provides a unique, mechanistic perspective on leveraging proteoform diversity in experimental design and drug discovery.

• Cycloheximide: Precision Protein Biosynthesis Inhibitor Work

  2026-08-06

  Cycloheximide, a gold-standard protein biosynthesis inhibitor from APExBIO, empowers researchers to dissect protein turnover and apoptosis with unmatched temporal control. This guide delivers actionable workflow enhancements, advanced troubleshooting, and strategic integration of cutting-edge findings in immuno-oncology.

• Cefiderocol’s In Vitro Efficacy Against Resistant Non-fermen

  2026-08-06

  This large-scale study evaluates cefiderocol’s in vitro activity against European Pseudomonas aeruginosa and Acinetobacter spp., including those resistant to meropenem and β-lactam/β-lactamase inhibitor combinations. The findings highlight cefiderocol’s superior efficacy and suggest its strategic value for tackling multidrug-resistant Gram-negative infections.

• GLT-1 Upregulation Mitigates TBI Pathology via CB1-CREB Inhi

  2026-08-05

  This study demonstrates that upregulating GLT-1 expression in mice after traumatic brain injury (TBI) reduces neuronal apoptosis and cognitive dysfunction by inhibiting the CB1-CREB signaling pathway. The findings clarify a mechanistic link between endocannabinoid modulation and glutamate transporter regulation, suggesting new angles for neuroprotection research.

• DFCP1 Directly Regulates ATGL-Mediated Lipid Droplet Lipolys

  2026-08-05

  This study identifies DFCP1 as a nutrient-sensitive regulator of lipid droplet catabolism via direct modulation of ATGL activity during starvation. The findings illuminate a new mechanism for lipid mobilization, relevant to metabolic disease research and the design of precise lipid metabolism assays.

450 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page